U.S. patent application number 13/570858 was filed with the patent office on 2012-11-29 for methods and apapratus for manually suspending intrathoracic impedance fluid status measurements.
This patent application is currently assigned to Medtronic, Inc.. Invention is credited to Denise Dirnberger, Douglas A. Hettrick, Melissa M. Rhodes, Shantanu Sarkar, Holly S. Vitense, Li Wang.
Application Number | 20120303085 13/570858 |
Document ID | / |
Family ID | 39205154 |
Filed Date | 2012-11-29 |
United States Patent
Application |
20120303085 |
Kind Code |
A1 |
Vitense; Holly S. ; et
al. |
November 29, 2012 |
METHODS AND APAPRATUS FOR MANUALLY SUSPENDING INTRATHORACIC
IMPEDANCE FLUID STATUS MEASUREMENTS
Abstract
The capability to suspend a patient alert relating to a
monitored physiologic parameters addresses a need to selectively
shut off a patient-alert signal or signals during the time a
patient is being treated for an excursion in the parameter. Of
course, in general a signal call attention to a patient's a
potentially deleterious status or condition for which they should
seek medical attention. Once a chronically-implanted monitoring
device has detected or provided information about the parameter
relative to a desired value, trend, or range and a clinician has
been notified and intervened the alert signal is temporarily
disabled for a predetermined period. That is, once the notification
occurs and alert has served its purpose, the alert mechanism is
selectively deactivated while the patient ostensibly begins to
gradually correct the monitored physiologic parameter under a
caregiver's direction and control. After which time, the alert will
reactivate.
Inventors: |
Vitense; Holly S.; (Maple
Grove, MN) ; Wang; Li; (Hong Kong, CN) ;
Dirnberger; Denise; (Blaine, MN) ; Rhodes; Melissa
M.; (Columbia Heights, MN) ; Hettrick; Douglas
A.; (Andover, MN) ; Sarkar; Shantanu; (St.
Paul, MN) |
Assignee: |
Medtronic, Inc.
Minneapolis
MN
|
Family ID: |
39205154 |
Appl. No.: |
13/570858 |
Filed: |
August 9, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11554825 |
Oct 31, 2006 |
|
|
|
13570858 |
|
|
|
|
Current U.S.
Class: |
607/28 |
Current CPC
Class: |
G16H 40/63 20180101;
A61N 1/37247 20130101; A61N 1/37258 20130101; A61B 5/0215 20130101;
A61B 5/053 20130101; A61B 5/0031 20130101 |
Class at
Publication: |
607/28 |
International
Class: |
A61N 1/365 20060101
A61N001/365 |
Claims
1. An apparatus for selectively deactivating a notification
function in an implantable medical device (IMD), comprising: means
for monitoring a physiologic parameter of a patient; means for
determining when the physiologic parameter one of exceeds a
threshold and departs from a desired range; means for energizing a
notification function to the patient responsive to one of the
parameter exceeding the threshold and departing from the desired
range; and means for preventing, for a preset period of time
subsequent to the patient receiving one of a corrective and a
palliative therapy under guidance of a clinician, energization of
the notification function responsive to one of the parameter
exceeding the threshold and departing from the desired range for a
during the preset period of time.
2. An apparatus according to claim 1, wherein the physiologic
parameter comprises one of an intra-thoracic fluid parameter and a
blood pressure parameter.
3. An apparatus according to claim 1, wherein the notification
function provides one of an audible sound and a tactile sensation
to the patient.
4. An apparatus according to claim 1, further comprising means for
displaying the physiologic parameter and an indication of the
status of the notification function on an external device
programming unit.
5. An apparatus according to claim 1, further comprising means for
continuing to monitor the physiologic parameter of the patient.
6. An apparatus according to claim 7, wherein the notification
function includes wirelessly broadcasting a notification to an
external receiver.
7. A non-transitory computer readable medium storing executable
instructions for carrying out a method of selectively deactivating
a notification function in an implantable medical device (IMD),
comprising: instructions for monitoring a physiologic parameter of
a patient; instructions for determining when the physiologic
parameter one of exceeds a threshold and departs from a desired
range; instructions for energizing a notification function to the
patient responsive to one of the parameter exceeding the threshold
and departing from the desired range; and instructions for
preventing, during a preset period of time subsequent to the
patient receiving one of a corrective and a palliative therapy
under guidance of a clinician, energization of the notification
function responsive to one of the parameter exceeding the threshold
and departing from the desired range during the preset period of
time.
8. A medium according to claim 7, wherein the physiologic parameter
comprises one of an intra-thoracic fluid parameter and a blood
pressure parameter.
9. A medium according to claim 7, wherein the notification function
provides one of an audible sound and a tactile sensation to the
patient.
10. A medium according to claim 7, further comprising instructions
for displaying the physiologic parameter and an indication of the
status of the notification function on an external device
programming unit.
11. A medium according to claim 7, further comprising instructions
for continuing to monitor the physiologic parameter of the
patient.
12. A medium according to claim 7, wherein the notification
function includes wirelessly broadcasting a notification to an
external receiver.
Description
RELATED APPLICATION
[0001] This application is a continuation of U.S. patent
application Ser. No. 11/554,825, filed Oct. 31, 2006 entitled
"METHODS AND APPARATUS FOR MANUALLY SUSPENDING INTRATHORACIC
IMPEDANCE FLUID STATUS MEASUREMENTS", herein incorporated by
reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to improved methods and
apparatus for monitoring the intra-thoracic fluid status of an
individual and selectively permitting a reduction in
notification(s) regarding the status during times when the status
is being acutely adjusted.
[0003] This patent disclosure hereby incorporates the entire
contents of co-pending non-provisional U.S. patent application Ser.
No. 10/727,008 filed 3 Dec. 2003 and entitled, "Method and
Apparatus for Detecting Change in Intrathoracic Electrical
Impedance" and U.S. Pat. No. 6,599,250 issued 29 Jul. 2003 to Webb
and Bennett and entitled, "Heart Failure Monitor Quicklook Summary
for Patient Management Systems."
SUMMARY
[0004] The capability to suspend a patient alert comes addresses a
need to selectively shut off a signal related to an undesirable
trend, range, or value of a physiologic parameter of a patient. For
instance, an audible patient-alert tone can be disabled during the
time a patient is being treated for an excursion in the parameter
(e.g., intra-thoracic fluid accumulation). Of course, in general an
alert signaling regime notifies a patient, caregiver, and/or
clinician attention of a potentially deleterious heart failure
event such as an acute decompensation for which they should seek
medical attention. In one embodiment, a chronically-implanted
intra-thoracic fluid status monitoring device is interrogated by an
external programming device and the patient evaluated and a
caregiver then can optionally suspend the alert notification
process for a predetermined period. Thus, according to the
invention once the patient notification or alert has occurred, the
alert mechanism is selectively deactivated while the patient
ostensibly begins to gradually correct the excursion under a
physician's direction and control. After a predetermined period of
time the alert will reactivate.
[0005] The inventive user interface (UI) screens described herein,
and their functionality, are designed to meet many of the following
user requirements: clinicians must not be forced to schedule a
special office visit to just turn on or off the alert and patients
then do not need to be subjected to undesired, frequent (e.g.,
daily) alert tones.
[0006] Ultimately, suspension of the alert must be implemented in a
way to preserve the feature's ability to detect a subsequent
excursion in the patient's fluid status (trend or acute readings).
Implementing alert suspension is designed so that it will not
affect the storage or graphing of the fluid status and/or fluid
status trend. The alert is thus suspended by programming a
"suspend" parameter (e.g., via a programmable-field window launched
from an external programmer for an implantable medical device). In
one form of the invention, a parameter-launched selection menu with
a response (i.e., yes/no) and a series of days (e.g., 2, 3, 5, 7,
9, 12, 14 days) selections. If a number of day selection is made,
below the value selection field, a text message will show when the
fluid status monitoring alert will resume (e.g., "resume alert on
30 Jan. 2005").
[0007] In addition, optionally a feedback loop acknowledges that
the alert was suspended by a notation added to the patient's report
and/or the trends on a long-term tracking report. A similar
notation can also appear in an events log so users can track the
operation of the intra-thoracic fluid status. To maintain
consistency, it is proposed that when an audible alert is
suspended, a related, complementary wireless transmission of same
can also be suspended.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] FIG. 1 illustrates in a schematic form an implantable
medical device according to an embodiment of the present
invention.
[0009] FIG. 2 depicts a schematic diagram of several exemplary
electrode configurations in an implantable medical device according
to an embodiment of the present invention.
[0010] FIG. 3 is a schematic diagram of an implantable medical
device in which the present invention may usefully be practiced
according to an embodiment of the present invention.
[0011] FIG. 4 is a functional block diagram of an exemplary
implantable medical device of the type illustrated in FIG. 3, in
which the present invention may usefully be practiced.
[0012] FIG. 5 depicts a graphical user interface having an overlay
menu in an embodiment of the invention relating to the OptiVol.RTM.
fluid status trend feature of Medtronic, Inc.
DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS
[0013] In the following detailed description, references are made
to illustrative embodiments for improved physiologic monitoring of
potentially deleterious and/or pathogenic patient conditions
wherein following clinical intervention notification signaling
schemes are temporarily suspended.
[0014] The present invention provides enhanced intra-thoracic
impedance measurements for the detection of hemodynamic changes, in
particular fluid retention. Three components of intra-thoracic
impedance are used to determine fluid overload; namely, 1) daily
thoracic impedance measurements, 2) thoracic reference impedance,
and 3) fluid index threshold. When the daily thoracic impedance and
reference impedance diverge the fluid index increases. Once the
fluid index passes the user programmable threshold, if enabled, an
audible alert sounds from the implantable device. The audible alert
will sound daily as long as the fluid index is greater than the
threshold. The capability to suspend the alert was designed to
address the situation whereby a patient and/or clinician simply
needs silence from the device alerts during, for example a recovery
period or when under acute observation in a clinical setting. As it
is currently designed, when enabled, the intra-thoracic impedance
algorithm triggers an audible device alert when, for instance, a
heart failure decomposition event is detected. After the patient
has been seen, evaluated, and properly treated by a clinician,
ideally the daily impedance should recover (i.e., increase) and
rejoin the reference impedance. Because the speed at which the
patient's daily impedance measurements change is typically more
rapid than the response of the thoracic impedance reference, the
alert can continue being activated for an extended period (e.g., on
a daily basis for several days) during a recovery period.
[0015] FIG. 1 is a schematic diagram of an implantable medical
device according to an embodiment of the present invention. In the
heuristic drawing of FIG. 1, a section of a body 11 is shown with a
cut-away area 12 to allow for illustration of an implantable
medical device according to an embodiment of the present invention.
As illustrated in FIG. 1, an exemplary embodiment of an implantable
medical device 10 includes two electrodes 15a and 15b on the
surface of a shell 14 of device 10. Power is provided to the
circuitry internal to the shell 14 by a power supply 18, which
drives a stimulation circuit 16, sending electrons through various
pathways in the body (such pathways are heuristically illustrated
as being primarily in the area surrounded by dotted line 13)
between electrodes 15a and 15b. An impedance measurement device 17
determines the impedance of the circuit pathway 13.
[0016] According to an embodiment of the present invention, because
of the possible poor signal characteristics that may be found using
the same electrodes for generating the impedance test pulse signal
and taking the measurement from the same electrodes, impedance
measurements are made in a uniform part (or relatively noiseless
area) of the field. One way to do this is using one electrode,
electrically isolated from the large surface indifferent electrode
(like the can or housing of a pacemaker, device 10, or other
implant) to deliver the test pulse, and a second electrically
isolated electrode to measure the voltage difference in the tissue
between the indifferent electrode and this second electrode.
Another embodiment can use two completely independent electrodes in
the field to measure the impedance, thus having a quadric-polar
system. In various configurations of this invention additional
electrodes can be imagined for flexibility where needed or to use
electrodes on leads locatable in specific places within the field
created by the test, or excite pulse.
[0017] FIG. 2 is a schematic diagram of exemplary electrode
configurations in an implantable medical device according to an
embodiment of the present invention. This acceptable variety of
configuration to achieve different impedance measurement signal
values is illustrated, for example, in FIG. 2 wherein an
implantable medical device has electrodes denoted e1, e2, eg and em
and either electrodes e1 or e2 can be used for developing the test
pulses. The value being measured (voltage or impedance of the
tissue between these electrode pairs) is taken between another
electrically isolated measuring electrode em and the indifferent or
ground electrode eg; between em and e1; or between em and e2. Or,
of course, the measurement could be taken between the two test
pulse delivery electrodes e1, and eg; or between e2 and eg in
another embodiment.
[0018] As will be described with reference to various figures
below, substantial variation can be used for each of the elements
described with reference to FIGS. 1-3, and still be within the
scope of this invention. For example, according to an embodiment of
the present invention, the excitation pulse is delivered between
electrodes e3 and eg and the value measured is taken between
electrodes e2 and eg. In a exemplary quadrapolar arrangement, the
excitation pulse is delivered between electrodes em and e3 and the
value measured is taken between electrodes e1 and e2.
[0019] FIG. 3 is a schematic diagram of an implantable medical
device in which the present invention may usefully be practiced
according to an embodiment of the present invention. As illustrated
in FIG. 3, an implantable medical device 100 according to an
embodiment of the present invention includes a ventricular lead 105
having an elongated insulative lead body 116 carrying three
mutually insulated conductors. Located adjacent the distal end of
the lead 105 are a ring electrode 124, an extendable helix
electrode 126, mounted retractably within an insulative electrode
head 128, and an elongated coil electrode 120. Each of the
electrodes 120, 124 and 126 is coupled to one of the three
conductors within the lead body 116. Electrodes 124 and 126 are
employed for cardiac pacing and for sensing ventricular
depolarizations, and electrode 120 is employed for cardioversion
and/or defibrillation and for sensing depolarizations, as described
below. At the proximal end of the lead 105 is a bifurcated
connector 114, which carries three electrical connectors, each
coupled to one of the coiled conductors.
[0020] An atrial/SVC lead 107 includes an elongated insulative lead
body 115, also carrying three mutually insulated conductors.
Located adjacent the J-shaped distal end of the lead 107 are a ring
electrode 121 and an extendible helix electrode 117, mounted
retractably within an insulative electrode head 119. Each of the
electrodes 117 and 121 is coupled to one of the conductors within
the lead body 115. Electrodes 117 and 121 are employed for atrial
pacing and for sensing atrial depolarizations. An elongated coil
electrode 123 is provided, proximal to electrode 121 and coupled to
the third conductor within the lead body 115. At the proximal end
of the lead 107 is a bifurcated connector 113, which carries three
electrical connectors, each coupled to one of the coiled
conductors.
[0021] Any other known lead configurations may also be utilized
other the lead configuration of FIG. 3. For example, coil electrode
123 could be located on ventricular lead 105 and positioned within
the atrium or SVC by ventricular lead 105 rather than by atrial
lead 107.
[0022] A coronary sinus/coronary vein lead 109 includes an
elongated insulative lead body 106, carrying three conductors, one
of which is coupled to an elongated coiled defibrillation electrode
108. Electrode 108, illustrated in broken outline, is located
within the coronary sinus and great vein of the heart. Located
adjacent the distal end of lead 109 is a ring electrode 125 and a
tip electrode 127. Each of electrodes 125-127 is coupled to one of
the remaining two of the three conductors located within lead body
106. At the proximal end of the lead 109 is a connector plug 104
that carries an electrical connector, coupled to the coiled
conductors.
[0023] The implantable medical device 100 includes a hermetically
sealed enclosure 111 containing the electronic circuitry (FIG. 4)
used for generating cardiac pacing pulses for delivering
cardioversion and defibrillation shocks and for monitoring the
patient's heart rhythm. Implantable medical device 110 is shown
with the lead connector assemblies 104, 113 and 114 inserted into
the connector block 112, which serves as a receptacle and
electrical connector for receiving the connectors 104, 113 and 114
and interconnecting the leads to the circuitry within enclosure
111.
[0024] Insulation of the outward facing portion of the housing 111
of the implantable medical device 110 may be provided or a portion
130 of the outward facing portion may instead be left uninsulated,
or some other division between insulated and uninsulated portions
may be employed. The uninsulated portion 130 of the housing 111
optionally serves as a subcutaneous defibrillation electrode, used
to defibrillate either the atria or ventricles, and as a sensing
electrode for sensing depolarizations of the heart. Other lead
configurations and electrode locations may of course be substituted
for the lead set illustrated. For example, atrial defibrillation
and sensing electrodes might be added to either the coronary sinus
lead or the right ventricular lead instead of being located on a
separate atrial lead, allowing for a two lead system.
[0025] FIG. 4 is a functional block diagram of an exemplary
implantable medical device of the type illustrated in FIG. 3, in
which the present invention may usefully be practiced. The device
is provided with a lead system including electrodes, which may be
as illustrated in FIG. 3. Alternate lead systems may of course be
substituted such as pericardial, epicardial, subcutaneous arrays,
pairs and single electrodes as is well understood by those of skill
in the art. If the electrode configuration of FIG. 3 is employed,
the correspondence to the illustrated electrodes is as follows.
Electrode 311 corresponds to an electrode formed along the
uninsulated portion 130 of the housing of the implantable medical
device 110. Electrode 320 corresponds to electrode 120 and is a
defibrillation electrode located in the right ventricle. Electrode
310 corresponds to electrode 108 and is a defibrillation electrode
located in the coronary sinus. Electrode 318 corresponds to
electrode 123 and is a defibrillation electrode located in the
superior vena cava. Electrodes 324 and 326 correspond to electrodes
124 and 126, and are used for sensing and pacing in the ventricle.
Electrodes 317 and 321 correspond to electrodes 117 and 121 and are
used for pacing and sensing in the atrium.
[0026] Electrodes 310, 311, 318 and 320 are coupled to high voltage
output circuit 234. Electrodes 324 and 326 are coupled to an R-wave
amplifier, which preferably takes the form of an automatic gain
controlled amplifier providing an adjustable sensing threshold as a
function of the measured R-wave amplitude, included in a sense
amplifier circuit 200. A signal is generated on R-out line 202
whenever the signal sensed between electrodes 324 and 326 exceeds
the present sensing threshold.
[0027] Electrodes 317 and 321 are coupled to a P-wave amplifier,
which preferably also takes the form of an automatic gain
controlled amplifier providing an adjustable sensing threshold as a
function of the measured P-wave amplitude, included in sense
amplifier circuit 200. A signal is generated on P-out line 206
whenever the signal sensed between electrodes 317 and 321 exceeds
the present sensing threshold. Numerous prior art sense amplifiers
employed in implantable cardiac pacemakers, defibrillators and
monitors may be usefully be employed in conjunction with the
present invention.
[0028] Switch matrix 208 is used to select which of the available
electrodes are coupled to wide band amplifier 210 for use in
digital signal analysis. Selection of electrodes is controlled by
the microprocessor 224 via data/address bus 218, which selections
may be varied as desired. Signals from the electrodes selected for
coupling to bandpass amplifier 210 are provided to multiplexer 220,
and thereafter converted to multi-bit digital signals by ND
converter 222, for storage in random access memory 226 under
control of direct memory access circuit 228. Microprocessor 224 may
employ digital signal analysis techniques to characterize the
digitized signals stored in random access memory 226 to recognize
and classify the patient's heart rhythm employing any of the
numerous signal processing methodologies known to the art.
[0029] Telemetry circuit 330 receives downlink telemetry from and
sends uplink telemetry to the patient activator by means of antenna
332. Data to be uplinked to the activator and control signals for
the telemetry circuit are provided by microprocessor 224 via
address/data bus 218. Received telemetry is provided to
microprocessor 224 via multiplexer 220. The atrial and ventricular
sense amp circuits of sense amplifier circuit 200 produce atrial
and ventricular EGM signals which also may be digitized and uplink
telemetered to an associated programmer on receipt of a suitable
interrogation command. The device may also be capable of generating
so-called marker codes indicative of different cardiac events that
it detects. The particular telemetry system employed is not
critical to practicing the invention, and any of the numerous types
of telemetry systems known for use in implantable devices may be
used. In particular, the prior telemetry systems as disclosed in
U.S. Pat. No. 5,292,343 issued to Blanchette et al., U.S. Pat. No.
5,314,450, issued to Thompson, U.S. Pat. No. 5,354,319, issued to
Wyborny et al. U.S. Pat. No. 5,383,909, issued to Keimel, U.S. Pat.
No. 5,168,871, issued to Grevious, U.S. Pat. No. 5,107,833 issued
to Barsness or U.S. Pat. No. 5,324,315, issued to Grevious, all
incorporated herein by reference in their entireties, are suitable
for use in conjunction with the present invention. However, the
telemetry systems disclosed in the various other patents cited
herein which are directed to programmable implanted devices, or
similar systems may also be substituted. The telemetry circuit 330
is of course also employed for communication to and from an
external programmer, as is conventional in implantable
anti-arrhythmia devices.
[0030] A patient notification circuit 331 enables the patient to be
notified in the event that it is determined that a significant
change in impedance has occurred, as will be in detail described
below.
[0031] The remainder of the circuitry is dedicated to the provision
of cardiac pacing, cardioversion and defibrillation therapies, and,
for purposes of the present invention may correspond to circuitry
known in the prior art. An exemplary apparatus is disclosed for
accomplishing pacing, cardioversion and defibrillation functions as
follows. The pacer timing/control circuitry 212 includes
programmable digital counters which control the basic time
intervals associated with DDD, VVI, DVI, VDD, AAI, DDI, DDDR, WIR,
DVIR, VDDR, AAIR, DDIR and other modes of single and dual chamber
pacing well known to the art. Circuitry 212 also controls escape
intervals associated with anti-tachyarrhythmia pacing in both the
atrium and the ventricle, employing, any anti-tachyarrhythmia
pacing therapies known to the art.
[0032] Intervals defined by pacing circuitry 212 include atrial and
ventricular pacing escape intervals, the refractory periods during
which sensed P-waves and R-waves are ineffective to restart timing
of the escape intervals and the pulse widths of the pacing pulses.
The durations of these intervals are determined by microprocessor
224, in response to stored data in memory 226 and are communicated
to the pacing circuitry 212 via address/data bus 218. Pacer
circuitry 212 also determines the amplitude of the cardiac pacing
pulses under control of microprocessor 224.
[0033] During pacing, the escape interval counters within pacer
timing/control circuitry 212 are reset upon sensing of R-waves and
P-waves as indicated by signals on lines 202 and 206, and in
accordance with the selected mode of pacing on time-out trigger
generation of pacing pulses by pacer output circuits 214 and 216,
which are coupled to electrodes 317, 321, 324 and 326. The escape
interval counters are also reset on generation of pacing pulses,
and thereby control the basic timing of cardiac pacing functions,
including anti-tachyarrhythmia pacing.
[0034] The durations of the intervals defined by the escape
interval timers are determined by microprocessor 224, via
data/address bus 218. The value of the count present in the escape
interval counters when reset by sensed R-waves and P-waves may be
used to measure the durations of R-R intervals, P-P intervals, PR
intervals and R-P intervals, which measurements are stored in
memory 226 and are used in conjunction with tachyarrhythmia
detection functions.
[0035] Microprocessor 224 operates as an interrupt driven device,
and is responsive to interrupts from pacer timing/control circuitry
212 corresponding to the occurrences of sensed P-waves and R-waves
and corresponding to the generation of cardiac pacing pulses. These
interrupts are provided via data/address bus 218. Any necessary
mathematical calculations to be performed by microprocessor 224 and
any updating of the values or intervals controlled by pacer
timing/control circuitry 212 take place following such interrupts.
Microprocessor 224 includes associated ROM in which the stored
program controlling its operation as described below resides. A
portion of the memory 226 may be configured as a plurality of
recirculating buffers, capable of holding series of measured
intervals, which may be analyzed in response to the occurrence of a
pace or sense interrupt to determine whether the patient's heart is
presently exhibiting atrial or ventricular tachyarrhythmia.
[0036] Arrhythmia detection may include any of the numerous
available prior art tachyarrhythmia detection algorithms. One
preferred embodiment may employ all or a subset of the rule-based
detection methods described in U.S. Pat. No. 5,545,186 issued to
Olson et al. or in U.S. Pat. No. 5,755,736 issued to Gillberg et
al., both incorporated herein by reference in their entireties.
However, any of the various arrhythmia detection methodologies
known to the art might also usefully be employed in alternative
embodiments of the invention.
[0037] In the event that an atrial or ventricular tachyarrhythmia
is detected, and an anti-tachyarrhythmia pacing regimen is desired,
timing intervals for controlling generation of anti-tachyarrhythmia
pacing therapies are loaded from microprocessor 224 into the pacer
timing and control circuitry 212, to control the operation of the
escape interval counters therein and to define refractory periods
during which detection of R-waves and P-waves is ineffective to
restart the escape interval counters.
[0038] In the event that generation of a cardioversion or
defibrillation pulse is required, microprocessor 224 employs the
escape interval counter to control timing of such cardioversion and
defibrillation pulses, as well as associated refractory periods. In
response to the detection of atrial or ventricular fibrillation or
tachyarrhythmia requiring a cardioversion pulse, microprocessor 224
activates cardioversion/defibrillation control circuitry 230, which
initiates charging of the high voltage capacitors 246, 248 via
charging circuit 236, under control of high voltage charging
control line 240. The voltage on the high voltage capacitors is
monitored via VCAP line 244, which is passed through multiplexer
220 and in response to reaching a predetermined value set by
microprocessor 224, results in generation of a logic signal,
terminating charging. Thereafter, timing of the delivery of the
defibrillation or cardioversion pulse is controlled by pacer
timing/control circuitry 212. Following delivery of the
fibrillation or tachycardia therapy the microprocessor then returns
the device to cardiac pacing and awaits the next successive
interrupt due to pacing or the occurrence of a sensed atrial or
ventricular depolarization. In the illustrated device, delivery of
the cardioversion or defibrillation pulses is accomplished by
output circuit 234, under control of control circuitry 230 via
control bus 238. Output circuit 234 determines whether a monophasic
or biphasic pulse is delivered, whether the housing 311 serves as
cathode or anode and which electrodes are involved in delivery of
the pulse.
[0039] A measurement circuit 203, similar to measurement circuit 37
and excitation circuit 34 described above in reference to FIG. 4,
is utilized in the delivery of excitation pulses and to measure the
resulting impedances between a vector formed by any pair of
electrodes selected from among electrodes 310, 311, 317, 318, 320,
321, 324 and 326 through connections made in switch matrix 208.
Measurement circuit 203, which is coupled to data/address bus 218,
can be separate from or may be included within sense amplification
circuit 200, as shown.
[0040] According to the present invention, once impedance
measurement is initiated by microprocessor 224, an excitation pulse
is generated by output circuit 234 and applied across an excitation
path corresponding to a vector formed by selected electrodes,
described above. The excitation pulse may be in the form of either
a current pulse or a voltage pulse, and, in either case, may
consist of one or more phases of differing polarity, or may
correspond to a monophasic, constant voltage pulse for simplicity
of implementation. In an embodiment of the present invention, for
example, the excitation pulse has an amplitude of approximately 1
volt and a pulse width of approximately 90 microseconds, although
any desired amplitude and pulse width may be utilized.
[0041] Measurement circuit 203 measures the voltage appearing
across a measurement path corresponding to selected measurement
electrodes, with the timing of the measurement by measurement
circuit 203 being time by timing and control circuit 212 so as to
be synchronized with delivery of the excitation pulse. Using the
current delivered across the excitation path and the voltage
measured across the measure path, microprocessor 224 then
calculates the apparent intra-thoracic impedance using Ohm's Law.
The process is repeated, so that multiple excitation pulses are
delivered over a multiple number of days to generate multiple
impedance measurements.
[0042] FIG. 5 depicts a graphical user interface (GUI) 500 having
an overlay menu 501,501' in an embodiment of the invention relating
to the OptiVol.RTM. intra-thoracic fluid status trend feature of
Medtronic, Inc. While a large variety of different GUI 500 can be
utilized in practicing the present invention, a nominal GUI 500 can
include, by illustration and without limitation some of the
following. The overlay 501' of GUI 500 is dedicated to a single
type of monitored physiologic parameter (as depicted intra-thoracic
impedance reflecting possible fluid accumulation within a portion
of the heart, lungs and/or pulmonary bed). A baseline reference
value can be manipulated via a user-selectable button 508 as a
threshold value 504 on GUI overlay 501' for ease of reference. The
urgency of the notification signal(s) can be adjusted via button
502 and the notification signal(s) can be suspended as indicated by
programmable and adjustable field 506. Once a suspension period has
been programmed an optional text message 510 can be configured to
display, for example, the date when the notification will again
become active. Of course, a similar function can be achieved with a
counter (incremental or decremental) in lieu of or in addition to
the depicted example.
[0043] In accordance with an aspect of the present invention,
methods and apparatus are provided for improving notification
signaling following a possibly deleterious excursion in a monitored
physiologic parameter of a patient.
[0044] In addition, it will be understood that specifically
described structures, functions and operations set forth in the
above-referenced patents can be practiced in conjunction with the
present invention, but they are not essential to its practice. It
is therefore to be understood, that within the scope of the
appended claims, the invention may be practiced otherwise than as
specifically described without actually departing from the spirit
and scope of the present invention.
* * * * *